Joint Formulary & PAD

Faricimab - Diabetic macular oedema

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravitreal injection
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Faricimab
Indication :
Diabetic macular oedema
Group Name :
Keywords :
DMO, anti-VEGF, ophthalmology
Brand Names Include :
Vabysmo
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
2

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the use of faricimab as a treatment option for treating Diabetic Macular Oedema in line with NICE TA799.

Faricimab will be given a RED traffic light status. Prescribing will be by hospital specialists only, in line with NICE TA799.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Other Indications

Below are listed other indications that Faricimab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Diabetic macular oedema.